Artiva Biotherapeutics, Common Stock Today
| ARTV Stock | 4.27 0.23 5.69% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Artiva Biotherapeutics, is selling for under 4.27 as of the 25th of March 2025; that is 5.69 percent up since the beginning of the trading day. The stock's lowest day price was 3.64. Artiva Biotherapeutics, has over 58 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Moving against Artiva Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Artiva Stock Highlights
| CEO President | Fred MD |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Artiva Biotherapeutics, Common (ARTV) is traded on NASDAQ Exchange in USA. It is located in 5505 Morehouse Drive, San Diego, CA, United States, 92121 and employs 82 people. Artiva Biotherapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 103.72 M. Artiva Biotherapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24.29 M outstanding shares of which 1.18 M shares are presently shorted by private and institutional investors with about 14.49 trading days to cover.
Artiva Biotherapeutics, generates negative cash flow from operations
Check Artiva Biotherapeutics, Probability Of Bankruptcy
Ownership AllocationArtiva Biotherapeutics, holds a total of 24.29 Million outstanding shares. The majority of Artiva Biotherapeutics, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Artiva Biotherapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Artiva Biotherapeutics,. Please pay attention to any change in the institutional holdings of Artiva Biotherapeutics, Common as this could imply that something significant has changed or is about to change at the company. Also note that nearly three million three hundred fifty-four thousand three hundred fifty-two invesors are currently shorting Artiva Biotherapeutics, expressing very little confidence in its future performance.
Check Artiva Ownership Details
Artiva Biotherapeutics, Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Artiva Biotherapeutics, market risk premium is the additional return an investor will receive from holding Artiva Biotherapeutics, long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.17) | |||
| Jensen Alpha | (1.45) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | 4.88 |
Artiva Stock Against Markets
Artiva Biotherapeutics, Corporate Management
| David Moriarty | Senior Operations | Profile | |
| Christopher Horan | Chief Officer | Profile | |
| Thorsten MD | Chief Officer | Profile | |
| Eugene Helsel | Senior Affairs | Profile |
Already Invested in Artiva Biotherapeutics, Common?
The danger of trading Artiva Biotherapeutics, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Artiva Biotherapeutics, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Artiva Biotherapeutics,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Artiva Biotherapeutics, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.